Patrícia Molz

Mrs. Patrícia Molz


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 December 2017 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PMPatrícia Molz
Patrícia Molz
NSNadja Schröder
Nadja Schröder
The aging process comprises a series of organic alterations, affecting multiple systems, including the nervous system. Aging has been considered the main risk factor for the advance of neurodegenerative diseases, many of which are accompanied by cognitive impairment. Aged individuals show cognitive decline, which has been associated with oxidative stress, as well as mitochondrial, and consequently energetic failure. Lipoic acid (LA), a natural compound present in food and used as a dietary supplement, has been considered a promising agent for the treatment and/or prevention of neurodegenerative disorders. In spite of a number of preclinical studies showing beneficial effects of LA in memory functioning, and pointing to its neuroprotective potential effect, to date only a few studies have examined its effects in humans. Investigations performed in animal models of memory loss associated to aging and neurodegenerative disorders have shown that LA improves memory in a variety of behavioral paradigms. Moreover, cell and molecular mechanisms underlying LA effects have also been investigated. Accordingly, LA displays antioxidant, antiapoptotic, and anti-inflammatory properties in both in vivo and in vitro studies. In addition, it has been shown that LA reverses age-associated loss of neurotransmitters and their receptors, which can underlie its effects on cognitive functions. The present review article aimed at summarizing and discussing the main studies investigating the effects of LA on cognition as well as its cell and molecular effects, in order to improve the understanding of the therapeutic potential of LA on memory loss during aging and in patients suffering from neurodegenerative disorders, supporting the development of clinical trials with LA.

1 February 2015 in Nutrition
Verified
Journal Article
Closed access
Joel Henrique EllwangerJoel Henrique Ellwanger
Joel Henrique Ellwanger
PMPatrícia Molz
Patrícia Molz
DDDanieli Rosane Dallemole
Danieli Rosane Dallemole
ASAriana Pereira dos Santos
Ariana Pereira dos Santos
TMTalise Ellwanger Müller
Talise Ellwanger Müller
JHJoão Antonio Pêgas Henriques
João Antonio Pêgas Henriques

1 May 2013 in Mutation Research - Genetic Toxicology and Environmental Mutagenesis
Verified
Journal Article
Closed access
CPCamila Schreiner Pereira
Camila Schreiner Pereira
PMPatrícia Molz
Patrícia Molz
RPRoberta Passos Palazzo
Roberta Passos Palazzo
TFThiago Aley Brites de Freitas
Thiago Aley Brites de Freitas
SMSharbel Maluf
Sharbel Maluf
SFSilvia Isabel Rech Franke
Silvia Isabel Rech Franke

29 October 2019 in Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
VUVanise Hallas Uberti
Vanise Hallas Uberti
BFBetânia Souza de Freitas
Betânia Souza de Freitas
PMPatrícia Molz
Patrícia Molz
EBElke Bromberg
Elke Bromberg
NSNadja Schröder
Nadja Schröder

1 April 2019 in Mutation Research - Genetic Toxicology and Environmental Mutagenesis
Verified
Journal Article
Closed access
TBTatiana T. Borba
Tatiana T. Borba
PMPatrícia Molz
Patrícia Molz
DSDiene S. Schlickmann
Diene S. Schlickmann
CSCaroline Santos
Caroline Santos
COCaio F. Oliveira
Caio F. Oliveira
SFSilvia I.R. Franke
Silvia I.R. Franke

25 July 2013 in BioMed Research International
Verified
Journal Article
Open access
PDF file
SFSilvia Isabel Rech Franke
Silvia Isabel Rech Franke
LMLuiza Louzada Müller
Luiza Louzada Müller
MSMaria Carolina Santos
Maria Carolina Santos
AFArcênio Fishborn
Arcênio Fishborn
LHLiziane Hermes
Liziane Hermes
DPDaniel Prá
Daniel Prá
Hyperglycemia leads to the formation of free radicals and advanced glycation end-products (AGEs). Antioxidants can reduce the level of protein glycation and DNA damage. In this study, we compared the levels of vitamin C intake, which is among the most abundant antioxidants obtained from diet, with the levels of fasting plasma glucose (FPG), glycated hemoglobin (A1C), DNA damage, and cytotoxicity in prediabetic subjects and type 2 diabetic subjects. Our results indicated that there was no significant correlation between FPG or A1C and DNA damage parameters (micronuclei, nucleoplasmic bridges, and nuclear buds). FPG and A1C correlated with necrosis (r=0.294;P=0.013andr=0.401;P=0.001, resp.). Vitamin C intake correlated negatively with necrosis and apoptosis (r=-0.246;P=0.040, andr=-0.276;P=0.021, resp.). The lack of a correlation between the FPG and A1C and DNA damage could be explained, at least in part, by the elimination of cells with DNA damage by either necrosis or apoptosis (cytotoxicity). Vitamin C appeared to improve cell survival by reducing cytotoxicity. Therefore, the present results indicate the need for clinical studies to evaluate the effect of low-dose vitamin C supplementation in type 2 diabetes.